ES2636944T3 - Aislamiento, identificación y caracterización de cepas con actividad probiótica a partir de heces de lactantes alimentados exclusivamente con leche materna - Google Patents

Aislamiento, identificación y caracterización de cepas con actividad probiótica a partir de heces de lactantes alimentados exclusivamente con leche materna Download PDF

Info

Publication number
ES2636944T3
ES2636944T3 ES14190648.7T ES14190648T ES2636944T3 ES 2636944 T3 ES2636944 T3 ES 2636944T3 ES 14190648 T ES14190648 T ES 14190648T ES 2636944 T3 ES2636944 T3 ES 2636944T3
Authority
ES
Spain
Prior art keywords
feces
breast milk
strains
characterization
isolation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14190648.7T
Other languages
English (en)
Inventor
José María VIEITES FERNÁNDEZ
Sergio MUÑOZ QUEZADA
Inmaculada Llamas Company
José MALDONADO LOZANO
Fernando Romero Braquehais
Antonio Francisco SUÁREZ GARCÍA
Ángel GIL HERNÁNDEZ
Carolina GÓMEZ LLORENTE
Miriam BERMÚDEZ BRITO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hero AG
Original Assignee
Hero AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hero AG filed Critical Hero AG
Application granted granted Critical
Publication of ES2636944T3 publication Critical patent/ES2636944T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/175—Rhamnosus
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/51—Bifidobacterium
    • A23V2400/519—Breve
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pediatric Medicine (AREA)
  • Communicable Diseases (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oncology (AREA)

Abstract

Una cepa de microorganismo probiotico aislada de heces de ninos alimentados exclusivamente con leche materna caracterizada porque consiste en Bifidobacterium breve HERO 15B con numero de referencia CNCM I-4035, depositada el 2 de julio de 2008 en el CNCM National Collection of Microorganism Culture, Pasteur Institute 25, Rue du Docteur Roux, F-75724 Paris.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19
imagen20
imagen21
imagen22
imagen23
imagen24
imagen25
imagen26
imagen27
imagen28
imagen29
imagen30
imagen31

Claims (1)

  1. imagen1
    imagen2
ES14190648.7T 2009-03-10 2010-03-09 Aislamiento, identificación y caracterización de cepas con actividad probiótica a partir de heces de lactantes alimentados exclusivamente con leche materna Active ES2636944T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
WOPCT/ES2009/000130 2009-03-10
PCT/ES2009/000130 WO2010103132A1 (es) 2009-03-10 2009-03-10 Aislamiento, identificación y caracterización de cepas con actividad probiótica a partir de heces de lactantes alimentados exclusivamente con leche materna

Publications (1)

Publication Number Publication Date
ES2636944T3 true ES2636944T3 (es) 2017-10-10

Family

ID=42727821

Family Applications (3)

Application Number Title Priority Date Filing Date
ES14190648.7T Active ES2636944T3 (es) 2009-03-10 2010-03-09 Aislamiento, identificación y caracterización de cepas con actividad probiótica a partir de heces de lactantes alimentados exclusivamente con leche materna
ES10750390.6T Active ES2532095T3 (es) 2009-03-10 2010-03-09 Aislamiento, identificacion y caracterizacion de cepas con actividad probiotica a partir de heces de lactantes alimentados exclusivamente con leche materna
ES14190638.8T Active ES2632436T3 (es) 2009-03-10 2010-03-09 Aislamiento, identificación y caracterización de cepas con actividad probiótica a partir de heces de lactantes alimentados exclusivamente con leche materna

Family Applications After (2)

Application Number Title Priority Date Filing Date
ES10750390.6T Active ES2532095T3 (es) 2009-03-10 2010-03-09 Aislamiento, identificacion y caracterizacion de cepas con actividad probiotica a partir de heces de lactantes alimentados exclusivamente con leche materna
ES14190638.8T Active ES2632436T3 (es) 2009-03-10 2010-03-09 Aislamiento, identificación y caracterización de cepas con actividad probiótica a partir de heces de lactantes alimentados exclusivamente con leche materna

Country Status (8)

Country Link
US (3) US8637297B2 (es)
EP (3) EP2848681B1 (es)
CN (3) CN102421889B (es)
DK (3) DK2407532T3 (es)
ES (3) ES2636944T3 (es)
PL (3) PL2848682T3 (es)
RU (1) RU2551315C2 (es)
WO (2) WO2010103132A1 (es)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
BRPI0809448A2 (pt) * 2007-03-28 2014-09-09 Alimentary Health Ltd Cepas de bifidobacterium probióticas
EP3424515A3 (en) 2010-08-04 2019-06-19 Thomas Julius Borody Stool collection devices and methods for using them
US9968638B2 (en) 2011-03-09 2018-05-15 Regents Of The University Of Minnesota Compositions and methods for transplantation of colon microbiota
RU2453591C1 (ru) * 2011-04-21 2012-06-20 Общество с ограниченной ответственностью "Бифилюкс" Штамм lactobacillus rhamnosus, используемый для получения продукции, содержащей лактобактерии
KR101228035B1 (ko) * 2011-06-29 2013-01-30 주식회사 쎌바이오텍 신규한 유산균 및 이를 포함하는 당뇨병 예방 및 치료용 조성물
US9719144B2 (en) 2012-05-25 2017-08-01 Arizona Board Of Regents Microbiome markers and therapies for autism spectrum disorders
JP2016501010A (ja) * 2012-11-12 2016-01-18 コンパニ・ジェルベ・ダノンＣｏｍｐａｇｎｉｅ Ｇｅｒｖａｉｓ Ｄａｎｏｎｅ 体重増加及び／又はインスリン抵抗性を低減させるためのラクトバチルスラムノサス株の使用
ES2468040B1 (es) * 2012-11-13 2014-12-26 Instituto Nacional De Investigación Y Tecnología Agraria Y Alimentaria (Inia) Microorganismo aislado de leche materna y de heces de un lactante, y su uso como probiótico
CN102960599A (zh) * 2012-11-19 2013-03-13 陕西科技大学 一种含益生元的双歧杆菌微胶囊的制备方法
ITRM20130174A1 (it) * 2013-03-22 2014-09-23 Eurospital S P A Ceppo di lactobacillus e suo uso come probiotico
ES2683190T3 (es) * 2013-08-09 2018-09-25 Ab-Biotics S.A. Probiótico para el llanto infantil excesivo
ITMI20131467A1 (it) 2013-09-06 2015-03-07 Sofar Spa Uso di una composizione comprendente microrganismi per aumentare la produzione intestinale di acido butirrico, di acido folico o di niacina e/o per diminuire la produzione intestinale di acido succinico
WO2015042683A1 (en) * 2013-09-26 2015-04-02 Hassan Firoozmand Biopolymer compositions comprising a plurality of treated single-celled microorganisms
CN106103696B (zh) 2014-03-24 2020-01-17 大塚制药株式会社 新颖的拟干酪乳杆菌菌株
MA39710A (fr) 2014-04-23 2015-10-29 Sofar Spa Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin
RU2605626C2 (ru) * 2015-04-28 2016-12-27 Федеральное государственное бюджетное образовательное учреждение высшего образования "Кемеровский технологический институт пищевой промышленности (университет)" Способ получения бактериального препарата с пробиотической активностью
BR112017024264B1 (pt) 2015-05-14 2022-07-12 Crestovo Holdings Llc Composições para transplante de flora fecal e métodos de preparação e utilização das mesmas, e dispositivos para sua administração
KR102534545B1 (ko) 2015-05-22 2023-05-18 아리조나 보드 오브 리젠츠 온 비하프 오브 아리조나 스테이트 유니버시티 자폐 스펙트럼 장애 및 관련된 증상을 치료하는 방법
CN104894021B (zh) * 2015-06-03 2018-02-09 宜兰食品工业股份有限公司 一种副干酪乳杆菌及其应用
CN105176822B (zh) * 2015-10-23 2019-01-11 广州康泽医疗科技有限公司 一种人类肠道益生菌的优化分离方法
ITUA20164188A1 (it) 2016-06-08 2017-12-08 Sofar Spa Nuovo uso medico di probiotici
US20170360848A1 (en) 2016-06-15 2017-12-21 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
US10849936B2 (en) 2016-07-01 2020-12-01 Regents Of The University Of Minnesota Compositions and methods for C. difficile treatment
US20180036352A1 (en) 2016-08-03 2018-02-08 Crestovo Holdings Llc Methods for treating ulcerative colitis
WO2018071537A1 (en) 2016-10-11 2018-04-19 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
WO2018071536A1 (en) 2016-10-11 2018-04-19 Crestovo Holdings Llc Compositions and methods for treating primary sclerosing cholangitis and related disorders
US10092601B2 (en) 2016-10-11 2018-10-09 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
IT201600122724A1 (it) 2016-12-02 2018-06-02 Sofar Spa Exopolysaccharides and uses thereof
IT201600127498A1 (it) 2016-12-16 2018-06-16 Sofar Spa Probiotici per uso nella diverticolosi e malattia diverticolare
EP3606541A1 (en) 2017-04-05 2020-02-12 Crestovo Holdings LLC Compositions and methods for treating parkinson's disease (pd) and related disorders
US11040073B2 (en) 2017-04-05 2021-06-22 Finch Therapeutics Holdings Llc Compositions and methods for treating diverticulitis and related disorders
JP2020521760A (ja) 2017-05-26 2020-07-27 クレストヴォ・ホールディングス・エルエルシー 糞便微生物ベースの治療剤を含む凍結乾燥組成物ならびにそれを製造および使用する方法
JP2020530494A (ja) 2017-08-07 2020-10-22 フィンチ セラピューティクス、インコーポレイテッド． 健康な腸バリアを維持及び回復するための組成物及び方法
WO2019136186A2 (en) * 2018-01-03 2019-07-11 Evolve Biosystems, Inc. Method for determining dysbiosis in the intestinal microbiome
EP3735456B1 (en) * 2018-01-05 2024-04-10 Bened Biomedical Co., Ltd. A novel lactic acid bacteria and its applications
CN108315285A (zh) * 2018-05-08 2018-07-24 西藏高原之宝牦牛乳业股份有限公司 一种副干酪乳杆菌及其制备方法
WO2020006663A1 (zh) * 2018-07-02 2020-01-09 葡萄王生技股份有限公司 用于改善代谢症候群的新颖副干酪乳杆菌 gks6、其培养基、培养方法、用途、医药组合物及可食用组合物
US11166990B2 (en) 2018-07-13 2021-11-09 Finch Therapeutics Holdings Llc Methods and compositions for treating ulcerative colitis
CN109134628A (zh) * 2018-09-26 2019-01-04 福建傲农生物科技集团股份有限公司 一种乳酸菌素plnE及其制备方法
EP3856212A1 (en) 2018-09-27 2021-08-04 Finch Therapeutics Holdings LLC Compositions and methods for treating epilepsy and related disorders
CN109536415B (zh) * 2018-12-26 2021-12-07 江西仁仁健康产业有限公司 一种鼠李糖乳杆菌及其应用
CN112912088B (zh) 2019-01-16 2024-12-24 N·V·努特里奇亚 用于轮状病毒引起的感染的具有非消化性寡糖的经发酵配方食品
US11865151B2 (en) * 2019-02-14 2024-01-09 Gutsybio Inc. Live biotherapeutics for the treatment of carbohydrate disorders
EP3718416B1 (en) 2019-04-03 2024-05-29 COREE S.r.l. Production method to increase bioavailability of sugars from natural complex polysaccharides for human, animal and agricultural purposes
KR102139687B1 (ko) * 2019-05-03 2020-07-30 주식회사 메디오젠 가드네렐라 바기날리스 및 칸디다 알비칸스에 항균 효과를 갖는 질염 치료 또는 개선용 유산균 mg4288
PH12021553137A1 (en) 2019-07-19 2022-07-25 Finch Therapeutics Holdings Llc Methods and products for treatment of gastrointestinal disorders
JP7013419B2 (ja) * 2019-08-07 2022-02-15 日清食品ホールディングス株式会社 炎症性サイトカインの産生誘導活性は低いが抗炎症性サイトカインの産生誘導活性が高いビフィズス菌
US11751597B2 (en) 2019-11-05 2023-09-12 Alfasigma S.P.A. Compositions comprising bacterial strains for use in increasing the bioavailability of amino acids derived from proteins, and related food product methods and systems
IT201900020422A1 (it) * 2019-11-05 2021-05-05 Sofar Spa Composizioni comprendenti ceppi di batteri per uso per aumentare la biodisponibilità degli amminoacidi derivanti da proteine
EP3725167A1 (en) * 2019-11-11 2020-10-21 COREE S.r.l. Synergistic blends of probiotics expressing improved beneficial activity for human host favourably interacting with food, particularly baby food
KR102296286B1 (ko) * 2020-06-16 2021-09-01 주식회사 바이오뱅크힐링 락토바실러스 람노서스 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
WO2021242057A1 (ko) * 2020-05-28 2021-12-02 주식회사 바이오뱅크힐링 락토바실러스 속 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
CN113817622B (zh) * 2020-06-18 2023-05-26 青岛蔚蓝生物股份有限公司 一株具有减轻致癌物对人体细胞基因毒性作用的长双歧杆菌及其应用
CN111826312B (zh) * 2020-07-10 2022-03-25 江南大学 一株可缓解苯并芘暴露的鼠李糖乳杆菌及其应用
CN111733110B (zh) * 2020-07-17 2021-10-22 佛山市朗芯生物科技有限公司 副干酪乳杆菌及其在制备治疗溃疡性结肠炎药物中的应用
CN111944727B (zh) * 2020-08-24 2021-12-03 汤臣倍健股份有限公司 一种短双歧杆菌207-1及其应用
CN113265351B (zh) * 2021-05-11 2022-05-06 昆明理工大学 一株乳杆菌w8172及其应用
RU2766765C1 (ru) * 2021-05-25 2022-03-15 Федеральное государственное бюджетное учреждение "Детский научно-клинический центр инфекционных болезней Федерального медико-биологического агентства" Способ лечения функциональных заболеваний желудочно-кишечного тракта у детей
CN113322216B (zh) * 2021-07-30 2021-11-05 北京量化健康科技有限公司 一种副干酪乳杆菌b111h及其在代谢综合征中的应用
KR102562507B1 (ko) * 2021-12-08 2023-08-02 한국식품연구원 항염증 효과가 뛰어난 신규한 락토바실러스 파라카제이 아종 톨러란스 WiKim0148 및 이의 용도
CN114113023B (zh) * 2021-12-16 2024-04-26 郑州轻工业大学 基于单核增生李斯特菌来源的氮掺杂碳点的制备方法和应用
CN114292779A (zh) * 2021-12-22 2022-04-08 清远西周生物医药科技有限公司 一种副干酪乳杆菌冻干粉、其应用及制备方法
CN114381411B (zh) * 2022-03-23 2022-05-27 山东中科嘉亿生物工程有限公司 乳酸乳球菌jyll-60及其在制备提高免疫力的产品上的应用
CN115998777B (zh) * 2022-10-18 2023-11-17 汤臣倍健股份有限公司 副干酪乳杆菌207-27的用途
CN116731891B (zh) * 2022-12-07 2024-05-07 内蒙古科拓生物有限公司 一株短双歧杆菌b2798及其制备益生菌制剂的用途
WO2024160209A1 (zh) * 2023-02-01 2024-08-08 北京三元食品股份有限公司 一株母乳来源的鼠李糖乳酪杆菌及应用
CN116396905B (zh) * 2023-04-08 2025-02-14 威凯海思(山东)生物工程有限公司 一种短双歧杆菌hc2953、菌剂及其应用
CN116855413B (zh) * 2023-07-07 2024-02-09 镇江远森医药科技有限公司 利用鼠李糖乳杆菌YSs069制备调节人体微生态平衡的生物活性物质及其应用
KR102700400B1 (ko) * 2023-11-24 2024-09-02 (주)마이크로바이옴 항균 활성 및 프로바이오틱스 특성을 갖는 글루텐 분해능이 있는 락토바실러스 파라카제이 glu70 균주 및 이의 용도
CN117660253B (zh) * 2023-12-10 2024-11-01 石河子大学 一种鼠李糖乳酪杆菌fmbl l23004 cnn、酸奶发酵剂、酸奶及其应用
PL248110B1 (pl) * 2023-12-27 2025-10-20 Politechnika Lodzka Szczep bakterii mlekowych Lacticaseibacillus rhamnosus
CN119193442B (zh) * 2024-11-29 2025-06-27 山东健源生物科技有限公司 一株可以清除机体内毒素的短双歧杆菌及其后生元
CN121046267A (zh) * 2025-10-31 2025-12-02 天赋能健康产业集团股份有限公司 短双歧杆菌在制备抗幽门螺杆菌导致的胃溃疡及胃部炎症的产品中的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69219768T2 (de) * 1992-07-06 1997-08-28 Societe Des Produits Nestle S.A., Vevey Milchbakterien
GB2338245B (en) * 1997-08-21 2001-11-21 New Zealand Dairy Board Immunity enhancing lactic acid bacteria
EP1034788A1 (en) * 1999-03-11 2000-09-13 Société des Produits Nestlé S.A. Lactic acid bacteria strains capable of preventing diarrhea
WO2000067583A2 (en) * 1999-05-07 2000-11-16 Compagnie Gervais Danone Use of lactic acid bacteria in the preparation of fermented milks for the treatment of depressed immunity levels
FI109602B (fi) * 2001-01-25 2002-09-13 Valio Oy Probioottiyhdistelmä
EP1384483A1 (en) * 2002-07-23 2004-01-28 Nestec S.A. Probiotics for treatment of irritable bowel disease (IBS) through improvement of gut neuromuscular function
PL1675481T3 (pl) * 2003-10-24 2009-03-31 Nutricia Nv Kompozycja synbiotyczna dla niemowląt
ITMI20042189A1 (it) * 2004-11-16 2005-02-16 Anidral Srl Composizione a base di batteri probiotici e suo uso nella prevenzione e-o nel trattamento di patologie e-o infezioni respiratorie e nel miglioramento della funzionalita' intestinale
CN1259054C (zh) * 2004-12-27 2006-06-14 孙文基 龙胆苦苷在制备抑制乙型肝炎病毒药物中的应用
AU2006233918B2 (en) * 2005-04-13 2012-06-21 Nestec S.A. Infant formula with probiotics
EP2269465A1 (en) * 2006-05-03 2011-01-05 Probiotical S.p.a. Compositions comprising Bifidobacterium adolescentis
CA2689862A1 (en) * 2006-06-09 2007-12-13 Nutravital Inc. Probiotic compositions comprising propionibacterium and uses thereof
US8066986B2 (en) * 2007-02-01 2011-11-29 Master Supplements, Inc. Formulations including digestive enzymes and polysorbate surfactants that enhance the colonization of administered probiotics microoganisms
EP1974743A1 (en) * 2007-03-28 2008-10-01 Nestec S.A. Probiotics to Improve Gut Microbiota
EP1997499A1 (en) * 2007-05-31 2008-12-03 Puleva Biotech, S.A. Mammalian milk microorganisms, compositions containing them and their use for the treatment of mastitis

Also Published As

Publication number Publication date
DK2407532T3 (en) 2015-03-09
EP2407532B1 (en) 2014-12-10
WO2010103140A2 (es) 2010-09-16
CN104232544A (zh) 2014-12-24
EP2848682A1 (en) 2015-03-18
CN104232545B (zh) 2017-11-21
US20120076829A1 (en) 2012-03-29
PL2848682T3 (pl) 2017-12-29
EP2407532A2 (en) 2012-01-18
DK2848682T3 (en) 2017-09-11
US20130280790A1 (en) 2013-10-24
US8637297B2 (en) 2014-01-28
PL2848681T3 (pl) 2017-10-31
CN104232544B (zh) 2017-04-12
EP2848682B1 (en) 2017-05-31
WO2010103132A1 (es) 2010-09-16
CN102421889B (zh) 2014-10-29
WO2010103140A3 (es) 2010-11-04
EP2407532A4 (en) 2013-04-10
PL2848681T4 (pl) 2017-10-31
CN102421889A (zh) 2012-04-18
ES2632436T3 (es) 2017-09-13
PL2407532T3 (pl) 2015-06-30
RU2551315C2 (ru) 2015-05-20
US20130280789A1 (en) 2013-10-24
RU2011138363A (ru) 2013-04-20
EP2848681A1 (en) 2015-03-18
EP2848681B1 (en) 2017-04-12
DK2848681T3 (en) 2017-07-24
ES2532095T3 (es) 2015-03-24
CN104232545A (zh) 2014-12-24

Similar Documents

Publication Publication Date Title
ES2636944T3 (es) Aislamiento, identificación y caracterización de cepas con actividad probiótica a partir de heces de lactantes alimentados exclusivamente con leche materna
ES2508566T3 (es) Cepas probióticas para su uso en mejorar el sistema nervioso entérico
Smelt et al. Probiotics can generate FoxP3 T-cell responses in the small intestine and simultaneously inducing CD4 and CD8 T cell activation in the large intestine
Smelt et al. L. plantarum, L. salivarius, and L. lactis attenuate Th2 responses and increase Treg frequencies in healthy mice in a strain dependent manner
Cencič et al. Functional cell models of the gut and their applications in food microbiology—a review
ES2616334T3 (es) Probióticos, IgA secretora e infección
ES2655697T3 (es) Mezcla de al menos 8 especies de bacterias de ácido láctico y/o bífidobacterias en la fabricación de masa madre
Yanagibashi et al. Bacteroides induce higher IgA production than Lactobacillus by increasing activation-induced cytidine deaminase expression in B cells in murine Peyer’s patches
ES2524432T3 (es) Bacterias del ácido láctico como cepas probióticas y composiciones que contienen las mismas
JP4942831B2 (ja) 抗アレルギー用組成物
DK1565547T4 (da) Probiotiske stammer, en fremgangsmåde til selektion deraf, præparater deraf samt anvendelse deraf
PE20001557A1 (es) Nueva cepa lactobacillus que previene diarrea causada por bacterias patogenas
RU2011150216A (ru) Детские питательные смеси, содержащие пробиотические микроорганизмы
ES2396501T3 (es) Cepa de Lactobacillus delbrueckii que disminuye el colesterol en sangre
PE20190417A1 (es) Uso de probioticos en el tratamiento y/o la prevencion de la dermatitis atopica
Vinderola et al. Phage-resistant mutants of Lactobacillus delbrueckii may have functional properties that differ from those of parent strains
Wang et al. Development of gut microbiota in a mouse model of ovalbumin-induced allergic diarrhea under sub-barrier system
AR071905A1 (es) Metodo para reducir borborigmos mediante la administracion de una bacteria bifidobacterium
ATE423196T1 (de) Antibiotikasensitive milchsäurebakterienstämme
CN206266585U (zh) 一种生产植物乳酸菌干燥粉用防堵装置
Das Should probiotics be used in the treatment of acute childhood diarrhea?
Tsutomu et al. BacteroidesInduce Higher IgA Production ThanLactobacillusby Increasing Activation-Induced Cytidine Deaminase Expression in B Cells in Murine Peyer’s Patches
Jeantet Innovative use of sweet whey to improve the viability of spray-dried probiotic bacteria
Martirosian et al. Intestinal anaerobic bacteria and autistic mind: is there some relations? Comment to: the autistic mind: a case study. Katarzyna Markiewicz, Bruce Duncan MacQueen. Med Sci Monit, 2009; 15 (1): CS5-13
Petito et al. P026 The impact of trophic effects of multi strain probiotic preparation on paracellular permeability